Coya Therapeutics has enrolled the 100th patient in its Phase 2/3 ALSTARS trial of COYA 302 for ALS. The study is expected to reach its 120-participant target in time for topline data in early Q2 2027, giving investors a defined clinical-development milestone to monitor.

Key Highlights

  • ALSTARS will randomize approximately 120 ALS patients equally among two COYA 302 dosing regimens and placebo.
  • The initial double-blind treatment period lasts 24 weeks, followed by a 24-week blinded active-treatment extension for eligible patients.
  • The trial’s primary endpoint measures change in ALSFRS-R total score through Week 24 against placebo.

Coya Therapeutics, Inc. (NASDAQ: COYA) has enrolled the 100th patient in its ongoing Phase 2/3 ALSTARS trial evaluating COYA 302 in amyotrophic lateral sclerosis. Based on current enrollment trends, Coya expects to complete enrollment of 120 participants in time to report topline data in early Q2 of 2027.

COYA 302 combines proprietary low-dose IL-2 with CTLA-4 Ig. Approximately 120 participants will be assigned equally among two pre-specified COYA 302 dosing regimens and placebo. The initial double-blind treatment period lasts 24 weeks, followed by a 24-week blinded active-treatment extension for patients who complete that phase. The trial also evaluates efficacy, safety, tolerability, biological activity and biomarker levels. Patients assigned to COYA 302 remain on their designated regimen during the extension phase.